Orally administered Taenia solium Calreticulin prevents experimental intestinal inflammation and is associated with a type 2 immune response-Reference-Cited by-同舟云学术

Orally administered Taenia solium Calreticulin prevents experimental intestinal inflammation and is associated with a type 2 immune response

Published:2017-10-16 Issue:10 Volume:12 Page:e0186510
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Mendlovic Fela^ORCID,Cruz-Rivera Mayra,Diaz-Gandarilla Jose Alfredo,Flores-Torres Marco Antonio,Avila Guillermina,Perfiliev Maria,Salazar Ana Maria,Arriaga-Pizano Lourdes,Ostrosky-Wegman Patricia,Flisser Ana

Funder

Papiit, DGAPA, UNAM

DGAPA, UNAM

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference58 articles.

1. Helminth-host immunological interactions: prevention and control of immune-mediated diseases;DE Elliott;Annals of the New York Academy of Sciences,2012

2. Helminth infections decrease host susceptibility to immune-mediated diseases;JV Weinstock;J Immunol,2014

3. Helminth infections and host immune regulation;HJ McSorley;Clinical microbiology reviews,2012

4. Human helminth therapy to treat inflammatory disorders- where do we stand?;H Helmby;BMC immunology,2015

5. Of worms, mice and man: an overview of experimental and clinical helminth-based therapy for inflammatory bowel disease;M Heylen;Pharmacology & therapeutics,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro immunoregulatory role of recombinant Ancylostoma ceylanicum calreticulin;Parasites, Hosts and Diseases;2024-02-23

2. Insights into the diagnosis, vaccines, and control of Taenia solium, a zoonotic, neglected parasite;Parasites & Vectors;2023-10-24

3. The many faces of parasite calreticulin;Frontiers in Immunology;2023-03-10

4. Eukaryotic expression and immunogenicity of Ancylostoma ceylanicum calreticulin;Parasitology International;2022-12

5. Opportunities and challenges for synthetic biology in the therapy of inflammatory bowel disease;Frontiers in Bioengineering and Biotechnology;2022-08-10